
Pfizer reported Q3 2025 revenues of $16.7 billion versus an estimate of $16.5B, with an adjusted EPS of $0.87, exceeding estimates of $0.63; the company is raising its full-year adjusted diluted EPS guidance to $3.00-$3.15.
Bullish
Pfizer is raising and narrowing its full-year 2025 adjusted diluted EPS guidance due to strong performance and an efficient cost structure.
Bearish
COVID-19 product revenues are declining due to lower vaccination and infection rates.